Today’s Rating On Watch: finnCap Analyst Reaffirmed GBX 100.00 Price Target on Abzena Plc (LON:ABZA) stock, While Reiterating Buy Rating

November 30, 2016 - By Winifred Garcia

Abzena Plc (LON:ABZA) Rating

The financial firm have set PT of GBX 100.00 on Abzena Plc (LON:ABZA) shares. This is 194.12% from the last stock price. In a research note revealed to investors on Wednesday, 30 November, finnCap maintained their Buy rating on shares of ABZA.

Abzena PLC (LON:ABZA) Ratings Coverage

Out of 2 analysts covering Abzena Plc (LON:ABZA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 100 is the highest target while GBX 98 is the lowest. The GBX 99 average target is 200.64% above today’s (GBX 32.93) stock price. Abzena Plc has been the topic of 12 analyst reports since September 14, 2015 according to StockzIntelligence Inc. As per Monday, October 12, the company rating was maintained by N+1 Singer. The firm has “Corporate” rating by N+1 Singer given on Thursday, January 7. The firm earned “Buy” rating on Tuesday, November 29 by FinnCap. The stock has “Buy” rating given by N+1 Singer on Monday, September 14. The stock has “Corporate” rating given by N+1 Singer on Wednesday, November 30. The rating was maintained by N+1 Singer on Tuesday, November 24 with “Corporate”. The rating was maintained by N+1 Singer on Friday, October 21 with “Corporate”. The stock of Abzena PLC (LON:ABZA) earned “Corporate” rating by N+1 Singer on Monday, January 25. The firm has “Buy” rating by FinnCap given on Friday, November 18. N+1 Singer maintained Abzena PLC (LON:ABZA) on Thursday, November 24 with “Corporate” rating.

About 102,500 shares traded hands or 1020.46% up from the average. Abzena PLC (LON:ABZA) has declined 34.34% since April 29, 2016 and is downtrending. It has underperformed by 39.57% the S&P500.

Abzena plc is a life sciences company. The company has a market cap of 45.30 million GBP. The Firm provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It currently has negative earnings. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Another recent and important Abzena PLC (LON:ABZA) news was published by Businesswire.com which published an article titled: “Abzena plc: Placing to Raise £20 Million and Acquisition” on November 24, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>